Loading…
Reported covered position: Legislative Ass't (Crapo) 10/06-12/10
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1 (Tax Cuts and Jobs Act)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2017 · third_quarter · 3A
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; TRICARE formulary and reimbursement issues.
Source: Senate LDA
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Further Continuing and Security Assistance Appropriations Act, 2017
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 2028 (continuing resolution to fund the federal government)
Strengthening Public Health Emergency Response Act of 2016
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
Preserving Access to Orphan Drugs Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill), orphan drug legislation (HR 3678)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), general vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), value of medicines (no specific bill), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education, no specific bill); Medicaid (no specific bill)
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), general vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), value of medicines (no specific bill), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), 21st Century Cures (H.R.6), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage)
Patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill), tax extenders bill
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
Patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Medicare Access and CHIP Reauthorization Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Medicare Access and CHIP Reauthorization Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Senate HELP Innovation Draft (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues
340B (no specific bill), Hepatitis C (general education; no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Innovation for Healthy Americans (no bill number), value of medicines (no specific bill), general pharmaceutical issues
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
340B (no specific bill), Hepatitis C (general education; no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Innovation for Healthy Americans (no bill number), value of medicines (no specific bill), general pharmaceutical issues
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Senate HELP Innovation Draft (no bill number)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill), tax extenders bill
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Fairness to Pet Owners (S.1200), general animal health issues
Fairness to Pet Owners (S.1200), general animal health issues
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Vaccines for Children Fund; Hospital Outpatient Prospective Payment proposed rule (CMS); Center for Medicare and Medicaid Innovation (CMMI) demonstration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2017 · fourth_quarter · Q4
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act; PAHPA (Pandemic and All Hazards Preparedness Act)
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Hospital Outpatient Prospective Payment proposed rule (CMS); Center for Medicare and Medicaid Innovation (CMMI) demonstration
H.R. 1 (Tax Cuts and Jobs Act)
Budget Appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2017 · third_quarter · Q3
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
Medicare Part D (general education, no specific bill); LIS Co-Pays (general education, no specific bill); Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Vaccines for Children Fund; Hospital Outpatient Prospective Payment proposed rule (CMS); Center for Medicare and Medicaid Innovation (CMMI) demonstration
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; TRICARE formulary and reimbursement issues.
340B (no specific bill), Hepatitis C (general education; no specific bill), Vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), Implementation of P.L.114-255 - 21st Century Cures Act, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2017 · first_quarter · 1A
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Issues related to international trade.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Patent reform; Legislative issues related to Pharmaceutical patent issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2017 · second_quarter · Q2
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Better Care Reconciliation Act (BCRA); FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; TRICARE formulary and reimbursement issues.
Medicare Part D (general education, no specific bill), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Antibiotics/stewardship; Vaccines for Children Fund; Hospital Outpatient Prospective Payment proposed rule (CMS)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2017 · first_quarter · Q1
Patent reform; Legislative issues related to Pharmaceutical patent issues.
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
MERCK & CO INC via MERCK & CO, INC.
2016 · fourth_quarter · Q4
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
H.R. 2028 (continuing resolution to fund the federal government)
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), 21st Century Cures (H.R.6), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage)
MERCK & CO INC via MERCK & CO, INC.
2016 · third_quarter · Q3
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill)
Patent settlements/pay for delay (general education)
Trans-Pacific Partnership, data exclusivity for biologics
MERCK & CO INC via MERCK & CO, INC.
2016 · second_quarter · Q2
Trans-Pacific Partnership, data exclusivity for biologics, United Nations high level panel
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), Strengthening Public Health Emergncy Response Act (H.R. 3299), priority review voucher and medical countermeasures (general education), women's health (general education), insurance benefit design and value-based contracting (general education), general pharmaceutical issues
MERCK & CO INC via MERCK & CO, INC.
2016 · first_quarter · Q1
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill), tax extenders bill
Trans-Pacific Partnership, data exclusivity for biologics
Patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
MERCK & CO INC via MERCK & CO, INC.
2015 · third_quarter · 3A
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
Trans-Pacific Partnership, data exclusivity for biologics
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2015 · fourth_quarter · Q4
Trans-Pacific Partnership, data exclusivity for biologics
Omnibus appropriations bill (general advocacy)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2015 · third_quarter · Q3
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Fairness to Pet Owners (S.1200), general animal health issues
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
MERCK & CO INC via MERCK & CO, INC.
2015 · second_quarter · Q2
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Senate HELP Innovation Draft (no bill number)
MERCK & CO INC via MERCK & CO, INC.
2015 · first_quarter · Q1
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
House of Representatives FY16 Budget Resolution, Senate FY16 Budget Resolution,
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
MERCK & CO INC via MERCK & CO, INC.
2014 · fourth_quarter · 4A
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
MERCK & CO INC via MERCK & CO, INC.
2014 · fourth_quarter · Q4
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · Q3
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · second_quarter · Q2
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Patent reform (H.R. 3309, S.1720)
Education on beta-agonists (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · first_quarter · Q1
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
MERCK & CO INC via MERCK & CO, INC.
2013 · fourth_quarter · Q4
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Drug Quality and Security Act (HR 3204)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2013 · third_quarter · Q3
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
Supply chain safety (H.R. 1919, S. 959, S. 957)
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill).
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation Part B demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education); Medicaid (no specific bill); Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs; Antibiotics/stewardship; Cost and value of prescription drugs; Vaccines for Children Program, Part B Drug Demonstration Proposed Rule; Medicare access to DXA services; Hospital Outpatient Prospective Payment proposed rule (CMS).
Issues related to international trade.
H.R. 2028 (continuing resolution to fund the federal government); S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2017/FY2018, Department of Defense Appropriations; Tricare formulary, reimbursement and vial size issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), House Republican tax blueprint, international tax proposals (no specific bill), orphan drug legislation (HR 3678)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education), shingles vaccine policies (general education), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), cost and value of medicines (no specific bill), priority review voucher, biodefense and medical countermeasures (general education), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, S. 3056 (CREATES Act), risk evaluation and mitigation strategies (general education), general pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), H.R. 5122 (Centers for Medicare and Medicaid Innovation demo), Independent Payment Advisory Board (general education, no specific bill), Medicare Part B (general education, no specific bill); Medicaid (no specific bill)
FY17 Labor HHS Appropriations bills, FY17 Agriculture Appropriations bills, vial size
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill); Medicaid (no specific bill)
340B (no specific bill), Hepatitis C (general education; no specific bill), general vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Senate Innovation Project (no bill number), value of medicines (no specific bill), general pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Fairness to Pet Owners (S.1200), general animal health issues
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill), tax extenders bill
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
340B (no specific bill), Hepatitis C (general education; no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Innovation for Healthy Americans (no bill number), value of medicines (no specific bill), general pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)
Trans-Pacific Partnership, data exclusivity for biologics
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Deficit reduction (no specific bill)
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill); R&D tax credit (no specific bill).
Patent reform (H.R. 3309, S. 1720 )
Deficit reduction (no specific bill); ADAP funding (no specific bill); omnibus appropriations...
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent reform (H.R. 3309)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)